EFTA01446908.txt Text dataset_10 View on DOJ

Illegal Activity
none
Blackmail
none
Date
2014-03-06
Document Type
research report
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:41
Summary
Deutsche Bank released a research report stating that the voluntary recall of Gilead's Atripla is a minor issue and reiterates a 'Buy' rating with a price target of $132. The recall was due to small particles found during a quality check by a third-party manufacturer, but management assures there is ample supply.
Metadata
Subject
Gilead Sciences - Atripla recall is NOT an issue - DB thoughts post mgmt convo
Sender
Recipients
Document ID
GILD.00
Date
2014-03-06
Relationships 3
Entity 1RelationshipEntity 2Description
Gilead Sciences Business Deutsche Bank Deutsche Bank provides research and analysis on Gilead Sciences.
Gilead Sciences Regulatory FDA Gilead Sciences reported a voluntary recall to the FDA.
Gilead Sciences Business 3rd party manufacturer Gilead Sciences uses a 3rd party manufacturer in China for Atripla.
Notable Quotes 3
Atripla recall is NOT an issue
Management reiterates that this is a very minor issue The company has more than enough Atripla supply.
The fundamental story on base biz and Sovaldi buy case intact. Reiterate Buy and $ 132 TP.
Financial Information
Amounts:132.0082.87125.731.51.517.2
Public Knowledge
Context
Recall of a pharmaceutical product is generally of interest to the public and media.
Media Worthy
Yes
Raw Analysis JSON click to expand
Themes
Financial transactions/money flowBusiness dealings
Organizations 4
Deutsche BankFDAGilead SciencesDeutsche Bank Securities Inc.
Locations 3
North AmericaUnited StatesChina
Text Analysis
Tone
Informative, reassuring
Purpose
To provide Deutsche Bank's analysis of Gilead Sciences' Atripla recall and reassure investors.
Significance
Provides insight into a potential issue affecting a major pharmaceutical company and its stock.
File Info
File Name
EFTA01446908.txt
Dataset
dataset_10
Type
Text
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:41:35.337242
DOJ Source
View on DOJ